

NIVS Communications 27/05/2022

Dear NIVS Colleague,

Please read and retain the below information.

Superuser email format: nhs.net or nhs.uk ONLY – Superusers Only

Estimated delivery date: 08th June 2022

Following further conversations with the Vaccination Programme and presenting them with your feedback, the requirement for Superusers to have an @nhs.net email for NIVS access has been extended to include email addresses with the nhs.uk suffix to be allowed continued access.

Please note that this is the only exception to this rule.

e.g.,

john.smith@nhs.net is acceptable

john.smith@uhl-tr.nhs.uk is acceptable

john.smith@nhs.gov.uk is **unacceptable**

The NIVS Team have contacted Superusers individually with non-compliant emails to advise them that they will have to request a new email address and the process of how to request a NHS email address for themselves and their business area.

If you as a Superuser do not have a compliant email address, your role will be changed to that of a Vaccinator after 08th June 2022.

If you are unaware of how to request a NHS email address, please contact the NIVS Team for assistance at NIVS@england.nhs.uk

Multi Factor Authentication: - Superusers Only

Estimated delivery date: 08th June 2022

To enhance the security of NIVS, we will be requiring Superusers to identify themselves by more than just a username and password. This will be in form of a PIN that will need to be entered into the logon screen of NIVS as provided by the Google Authenticator

An additional email will be sent providing instructions on how to install the Authenticator on your phone and the process of how to sign in with the authenticator.

Please note that a mobile device will be required from this date to allow Superusers to login to NIVS. If you as a Superuser do not have a mobile device and Google Authenticator installed, you will be unable to access NIVS after 08th June 2022.

Vaccine Name Change:

Estimated delivery date: w/c– 01st July 2022

To meet a Vaccination Programme requirement, the current AstraZeneca vaccine will be renamed in NIVS to:

Vaxzevria 0.5ml dose (AstraZeneca)

This will align the current Astrazeneca vaccine naming conventions to match other current Covid vaccines.

e.g.,

Spikevax 0.1mg/0.5ml dose (Moderna)

Comirnaty 30micrograms/0.3ml dose (Pfizer) .

Seven Day Limitation on Vaccination entry – All NIVS Users

Estimated delivery date: TBC

If you have any questions on any of the above, please contact nivs@england.nhs.uk

Kind regards,

National Immunisation & Vaccination System Support Team

Telephone: **0121 611 0187**

Email: nivs@england.nhs.uk

Web: <http://nivs.ardengemcsu.nhs.uk/home>



This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this email, or any disclosure or copying of its content, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.



Please consider the environment before printing this e-mail.